(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Fundamental Monetary Guidance for Going into Business - 2As tetanus vaccination rates decline, doctors worry about rising case numbers
- 3The most effective method to Go with Informed Choices on Vehicle Leases
- 4Merz: 80% of Syrians in Germany should return in three years
- 5The Way to Monetary Health: Individual budget Change
- Pick Your Favored kind of soup
- Explosions at Burundi ammunition depot kill civilians, witnesses say
- Europe’s Airlines Run Low on Fuel
- NASA troubleshoots Artemis II toilet problem in otherwise smooth flight
- Jersey's wellbeing score is below UK and France
- Peruvian ex-President Martin Vizcarra sentenced to 14 years in prison
- To fix a patient's irregular heartbeat, doctors first tested its digital 'twin'
- Vote in favor of your Number one Kind of Gems
- Do-It-Yourself Home Style on a Careful spending plan: Imaginative Thoughts and Tasks
